LONDON - Physiomics PLC (AIM: PYC), a company specializing in mathematical modeling and biostatistics, has collaborated with Astellas Pharma Inc. (TYO:4503) to publish a peer-reviewed article on optimizing treatment regimens for cancer immunotherapy. The study, titled "A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination with Pembrolizumab," appeared in the journal "CPT: Pharmacometrics & Systems Pharmacology."
The publication details the use of Physiomics' proprietary 'Virtual Tumour' platform to simulate various dosing strategies for an immunotherapy combination, aimed at informing the design of Phase-1 clinical studies. The research represents a significant step in the development of new oncology therapies, particularly in the realm of immunotherapy, which harnesses the immune system to combat cancer cells.
Cancer remains a leading cause of death globally, and the development of effective treatments is of paramount importance. Immunotherapies can be administered alone or in conjunction with other drugs to improve patient outcomes. However, determining the optimal dosage and schedule to balance efficacy with potential toxicity is a complex challenge, particularly when multiple drugs are used in combination.
The joint publication underscores the effectiveness of modeling and simulation in expediting the drug development process. By predicting the most promising treatment schedules during the transition from preclinical to clinical research, Physiomics' services aim to streamline and de-risk the development of new therapeutics.
Dr. Peter Sargent, CEO of Physiomics, expressed pride in the published work, highlighting the quality of the consultancy services provided to Astellas and the strength of their partnership. He also emphasized the utility of the Virtual Tumour Platform in advancing novel cancer treatments.
The collaboration between Physiomics and Astellas demonstrates the growing impact of computational approaches in the pharmaceutical industry, not only in the discovery phase but throughout the entire drug development cycle. The insights from the study are expected to contribute to the broader efforts in creating more effective cancer therapies.
This article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.